Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.660
-0.030 (-1.78%)
At close: Nov 21, 2024, 4:00 PM
1.690
+0.030 (1.81%)
After-hours: Nov 21, 2024, 7:56 PM EST
Protalix BioTherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -9.61 | 8.31 | -14.93 | -27.58 | -6.52 | -18.28 | |
| Depreciation & Amortization | 1.28 | 1.19 | 1.09 | 1.12 | 1.3 | 1.62 | |
| Other Amortization | 0.06 | 0.27 | 0.3 | 2.67 | 3.47 | 2.99 | |
| Loss (Gain) From Sale of Assets | 0.01 | 0.01 | - | -0.05 | - | - | |
| Stock-Based Compensation | 3.97 | 3.45 | 2.09 | 2.38 | 3.13 | 0.84 | |
| Other Operating Activities | 0.54 | -4.01 | -1.53 | 1.28 | -0.35 | 0.31 | |
| Change in Accounts Receivable | 6.83 | -0.43 | -1.19 | -1.03 | 2.09 | 0.19 | |
| Change in Inventory | 4.38 | -2.24 | 1.15 | -4.87 | -4.93 | 0.41 | |
| Change in Accounts Payable | 0.81 | 5.3 | -4.8 | 2.39 | 2.27 | 2.74 | |
| Change in Unearned Revenue | - | -13.18 | -7.16 | 13.23 | -26.21 | -9.58 | |
| Change in Other Net Operating Assets | 0.01 | 0.01 | -0.01 | 0.19 | -0.36 | -0.59 | |
| Operating Cash Flow | 8.28 | -1.32 | -25 | -10.29 | -26.11 | -19.36 | |
| Capital Expenditures | -1.11 | -1.15 | -0.63 | -1.46 | -0.66 | -0.63 | |
| Sale of Property, Plant & Equipment | 0 | - | - | 0.05 | - | - | |
| Investment in Securities | 20.42 | -15.42 | -5 | 20 | -20 | - | |
| Other Investing Activities | -0.12 | -0.14 | 0.59 | 0.33 | 0.7 | -0.26 | |
| Investing Cash Flow | 19.2 | -16.71 | -5.04 | 18.92 | -19.95 | -0.88 | |
| Short-Term Debt Repaid | - | - | - | -4.09 | - | - | |
| Long-Term Debt Repaid | - | - | - | -30.04 | -0.22 | - | |
| Total Debt Repaid | -20.42 | - | - | -34.12 | -0.22 | - | |
| Net Debt Issued (Repaid) | -20.42 | - | - | -34.12 | -0.22 | - | |
| Issuance of Common Stock | - | 24.67 | 8.24 | 46.2 | 46.68 | - | |
| Financing Cash Flow | -20.42 | 24.67 | 8.24 | 12.08 | 46.47 | - | |
| Foreign Exchange Rate Adjustments | -0.06 | -0.11 | -0.08 | 0.01 | 0.06 | 0.23 | |
| Net Cash Flow | 7 | 6.52 | -21.87 | 20.72 | 0.47 | -20.02 | |
| Free Cash Flow | 7.17 | -2.47 | -25.63 | -11.74 | -26.76 | -19.99 | |
| Free Cash Flow Margin | 15.70% | -3.77% | -53.80% | -30.62% | -42.55% | -36.54% | |
| Free Cash Flow Per Share | 0.10 | -0.03 | -0.53 | -0.27 | -0.92 | -1.35 | |
| Cash Interest Paid | 2.74 | 2.74 | 2.2 | 3.41 | 4.34 | 4.34 | |
| Levered Free Cash Flow | 9.03 | -1.81 | -7.55 | -12.86 | -7.79 | 3.4 | |
| Unlevered Free Cash Flow | 10.11 | -0.09 | -6.27 | -10.83 | -5.22 | 5 | |
| Change in Net Working Capital | -12.06 | 10.11 | 0.68 | 0.08 | 10.69 | -9.87 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.